Hot Flashes Market 2027
DelveInsight's 'Hot Flashes - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hot Flashes in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hot Flashes from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Study Period: 2016-2027
Hot Flashes - Disease Understanding and Treatment Algorithm
Hot flashes (HF) are often described as episodic sensations of heat, intense sweating, and flushing affecting the face and chest, which are often accompanied by palpitations and anxiety. Each particular episode lasts 3-10 minutes and episodes can recur with varying frequency. Some women experience hot flashes hourly or daily, whereas for others they may occur occasionally. The age at onset of hot flashes also varies from woman to woman. Hot flashes typically begin as the sudden sensation of heat centered on the upper chest and face. When moderate or severe, the hot flash rapidly become generalized, lasts from 2 to 4 minutes, and can be associated with profuse perspiration, palpitations, or anxiety.
The DelveInsight Hot Flashes market report gives the thorough understanding of the Hot Flashes by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hot Flashes in the US, Europe, and Japan.
Hot Flashes Epidemiology
The Hot Flashes epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population of Hot Flashes Associated with Post-menopause and Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause] scenario of Hot Flashes in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, prevalent population of Hot Flashes associated with menopause in 7MM countries is expected to increase at a CAGR of 0.208% for the study period i.e. 2016-2027. As per the estimates, United States has the highest prevalent population of Hot Flashes associated with Post Menopause. Among the European countries, Germany had the highest prevalent population of Hot Flashes with 5,215,367 cases, followed by France which had prevalent population of 3,485,768 in 2016.
Hot Flashes Drug Chapters
This segment of the Hot Flashes report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic landscape of Hot Flashes associated with post-menopause can be divided into two major categories based on the class of drug; these are: Hormonal Therapies and Non-Hormonal Therapies. Detailed chapters of upcoming therapies such as TX-001HR (TherapeuticsMD), BHR-401 (Besins Healthcare), Donesta (Mithra Pharmaceuticals), Salubrin (PH-80; Pherin Pharmaceuticals), Fezolinetant (ESN364; Ogeda/Astellas) and NT-814 (Nerre Therapeutics) which are expected to launch during the forecast period [2018-2027] have also been covered in the report.
Hot Flashes Market Outlook
The Hot Flashes market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market size of Hot Flashes associated with Post-menopause in the seven major markets is expected to reach around USD 5,755.4 million by 2027. The United States accounts for the highest market size of Hot Flashes associated with Post-menopause in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. The increased risk of Hormonal therapies (Breast Cancer, Dementia, and Cardiovascular Diseases) for the treatment of HF associated with postmenopause led to a decline in prescription Hormonal medication. This has led to a decline in the overall market size for the treatment of HF in the US from 2016 to 2022. However, DelveInsight's analysts estimate that the market is expected to show positive growth post 2022, due to the increased patient prevalence and to the expected launch of emerging Hormonal Therapies and targeted non-hormonal therapies.
Hot Flashes Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of Hormonal therapies for Hot Flashes such as TherapeuticsMD (TX-001HR), Besins Healthcare (BHR-401), Mithra Pharmaceuticals (Donesta) and targeted Non-Hormonal Therapies such as Salubrin (PH-80; Pherin Pharmaceuticals), Fezolinetant (ESN364; Ogeda/Astellas) and NT-814 (Nerre Therapeutics) in the forecast period [2018-2027] will also create a positive impact on the Hot Flashes market.
Hot Flashes Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Hot Flashes Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Key Cross Competition
- Market Size by Therapies
- Drugs Uptake
Hot Flashes Report Assessment
- Pipeline Product Profiles
- Key Products and Key Players
- Market Drivers and Barriers
Key Benefits
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Hot Flashes market
- Organize sales and marketing efforts by identifying the best opportunities for Hot Flashes market
- To understand the future market competition in the Hot Flashes market.
1. Key Insights
2. Hot Flashes: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Hot Flashes in 2016
2.2. Total Market Share (%) Distribution of Hot Flashes in 2027
3. Hot Flashes associated with menopause: Disease Background and Overview
3.1. Introduction
3.2. Vasomotor Symptoms
3.3. Signs and Symptoms of VMS
3.4. Pathophysiology of VMS
3.5. Risk factors for VMS
3.6. Effects of VMS
3.7. Premature (early) Menopause
3.8. Menopause Associated with Breast Cancer Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
5. Total Prevalent Patient Population of Hot Flashes associated with Post-menopause in 7MM Countries
6. Country Wise-Epidemiology of Hot Flashes Associated with Post-menopause
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Hot Flashes Associated with Post-menopause in the United States
6.1.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in the United States
6.2. EU5 Countries
6.3. Germany
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalent Population of Hot Flashes Associated with Postmenopause in Germany
6.3.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in Germany
6.4. France
6.4.1. Assumptions and Rationale
6.4.2. Total Prevalent Population of Hot Flashes Associated with Post-menopause in France
6.4.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Postmenopause in France
6.5. Italy
6.5.1. Assumptions and Rationale
6.5.2. Total Prevalent Population of Hot Flashes Associated with Postmenopause in Italy
6.5.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Postmenopause in Italy
6.6. Spain
6.6.1. Assumptions and Rationale
6.6.2. Total Prevalent Population of Hot Flashes Associated with Postmenopause in Spain
6.6.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in Spain
6.7. The United Kingdom
6.7.1. Assumptions and Rationale
6.7.2. Total Prevalent Population of Hot Flashes Associated with Post-menopause in the UK
6.7.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in the UK
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Total Prevalent Population of Hot Flashes Associated with Post-menopause in Japan
6.8.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause in Japan
7. Treatment Algorithm, Current Treatment, and Medical Practices
7.1. Hormonal Therapies
7.1.1. Estrogen Replacement Therapies
7.1.2. Progestational Agents
7.2. Non-hormonal pharmacological treatments for vasomotor symptoms
7.2.1. Clonidine
7.2.2. Serotonin Reuptake Inhibitors
7.2.3. Gabapentin
7.2.4. Behavioral Modifications
7.3. Complementary alternative medicines (CAM):
8. Unmet Needs
9. Marketed drugs by class
9.1. Hormonal Therapies
9.1.1. Estrogen Only Therapies
9.1.2. Combination Therapies
9.2. Non-Hormonal Therapies
9.2.1. Approved Drug
9.2.2. Off-Label Antidepressants
10. Emerging Therapies
10.1. Key Cross Competition
10.2. TX-001HR: TherapeuticsMD
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. BHR-401 (Utrogestan): Besins Healthcare
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Product Profile
10.4. Prasterone + Acolbifene: Endoceutics
10.4.1. Product Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.4. Product Profile
10.5. MT-8554: Mitsubishi Tanabe Pharma
10.5.1. Product Description
10.5.2. Clinical Development
10.5.3. Product Profile
10.6. ESN364: Ogeda
10.6.1. Product Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.4. Safety and Efficacy
10.6.5. Product Profile
10.7. NT-814: Nerre Therapeutics
10.7.1. Product Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.4. Safety and Efficacy
10.7.5. Advantages and Disadvantages
10.7.6. Product Profile
10.8. Salubrin: Pherin Pharmaceuticals
10.8.1. Product Description
10.8.2. Other Developmental Activities
10.8.3. Clinical Development
10.8.4. Safety and Efficacy
10.8.5. Advantages and Disadvantages
10.8.6. Product Profile
10.9. Donesta: Mithra Pharmaceuticals (Donesta Biosciences)
10.9.1. Product Description
10.9.2. Other Developmental Activities
10.9.3. Clinical Development
10.9.4. Safety and Efficacy
10.9.5. Product Profile
10.10. FP-101: Fervent Pharmaceuticals
10.10.1. Product Description
10.10.2. Other Developmental Activities
10.10.3. Clinical Development
10.10.4. Product Profile
10.11. MLE4901 (AZD4901): Millendo Therapeutics
10.11.1. Product Description
10.11.2. Other Developmental Activities
10.11.3. Clinical Development
10.11.4. Safety and Efficacy
10.11.5. Advantages and Disadvantages
10.11.6. Product Profile
11. Hot Flashes: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of Hot Flashes associated with Post Menopause in 7MM
11.3. Market Size by Therapies in 7MM
12. The United States Market Outlook
12.1. United States Market Size
12.2. Total Market size of Hot Flashes in the United States
12.3. Market Size by Therapies in the United States
13. EU-5 Countries: Market Outlook
13.1. Germany: Market Outlook
13.1.1. Total Market size of Hot Flashes in Germany
13.1.2. Market Size by Therapies in Germany
13.2. France: Market Outlook
13.2.1. Total Market size of Hot Flashes in France
13.2.2. Market Size by Therapies in France
13.3. Italy: Market Outlook
13.3.1. Total Market size of Hot Flashes in Italy
13.3.2. Market Size by Therapies in Italy
13.4. Spain: Market Outlook
13.4.1. Total Market Size of Hot Flashes in Spain
13.4.2. Market Size by Therapies in Spain
13.5. United Kingdom: Market Outlook
13.5.1. Total Market size of Hot Flashes in the United Kingdom
13.5.2. Market Size by Therapies in the United Kingdom
13.6. Japan: Market Outlook
13.6.1. Total Market size of Hot Flashes in Japan
13.6.2. Market Size by Therapies in Japan
14. Market Drivers
15. Market Barriers
16. Appendix
16.1. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
Table 1 Conditions that may cause or mimic vasomotor events and that can be distinguished from menopausal symptoms by history, examination, and investigations
Table 2 Total Prevalent Patient Population of Hot Flashes associated with Post-menopause in 7MM Countries (2016-2027)
Table 3 Total Prevalent Population of Hot Flashes Associated with Post-menopause in the United States (2016-2027)
Table 4 Severity Specific Prevalence of Hot Flashes Associated with Postmenopause in the United States (2016-2027)
Table 5 Total Prevalent Population of Hot Flashes associated with Post Menopause in Germany (2016-2027)
Table 6 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Germany (2016-2027)
Table 7 Total Prevalent Population of Hot Flashes Associated with Post-menopause in France (2016-2027)
Table 8 Severity Specific Prevalence of Hot Flashes Associated with Postmenopause in France (2016-2027)
Table 9 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Italy (2016-2027)
Table 10 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Italy (2016-2027)
Table 11 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Spain (2016-2027)
Table 12 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Spain (2016-2027)
Table 13 Total Prevalent Population of Hot Flashes Associated with Post-menopause in the UK (2016-2027)
Table 14 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in the UK (2016-2027)
Table 15 Total Prevalent Population of Hot Flashes Associated with Post-menopause in Japan (2016-2027)
Table 16 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Japan (2016-2027)
Table 17 : Hot Flashes Treatments Algorithm
Table 18 Complementary and alternative medicines for the treatment of menopausal symptoms
Table 19 Emerging Drugs Analysis
Table 20 Emerging Drugs Analysis
Table 21 TX-001HR,Clinical Trial Description, 2018
Table 22 BHR-401,Clinical Trial Description, 2018
Table 23 Prasterone (DHEA) and acolbifene,Clinical Trial Description, 2018
Table 24 AQX-1125, Clinical Trial Description, 2018
Table 25 ESN364,Clinical Trial Description, 2018
Table 26 NT-814, Clinical Trial Description, 2018
Table 27 Salubrin,Clinical Trial Description, 2018
Table 28 Donesta, Clinical Trial Description, 2018
Table 29 FP-101, Clinical Trial Description, 2018
Table 30 MLE4901, Clinical Trial Description, 2018
Table 31 Market Size of Hot Flashes associated with Post Menopause in 7MM in USD Million (2016-2027)
Table 32 Market Size of Hot Flashes associated with Post Menopause in 7MM by therapies, in USD Million (2016-2027)
Table 33 US Market Size of Hot Flashes associated with Post Menopause in USD Million (2016-2027)
Table 34 Market Size of Hot Flashes associated with Post menopause by therapies in the US, USD Millions (2016-2027)
Table 35 Market Size of Hot Flashes associated with Post menopause in Germany, USD Millions (2016-2027)
Table 36 Market Size of Hot Flashes associated with Post Menopause by therapies in Germany, USD Millions (2016-2027)
Table 37 Market Size of Hot Flashes associated with Post Menopause in France, USD Millions (2016-2027)
Table 38 Market Size of Hot Flashes associated with Post Menopause by therapies in France, USD Millions (2016-2027)
Table 39 Market Size of Hot Flashes associated with Post menopause in Italy, USD Millions (2016-2027)
Table 40 Market Size of Hot Flashes associated with Post Menopause by therapies in Italy, USD Millions (2016-2027)
Table 41 Market Size of Hot Flashes associated with Post Menopause in Spain, USD Millions (2016-2027)
Table 42 Market Size of Hot Flashes associated with Post Menopause by therapies in Spain, USD Millions (2016-2027)
Table 43 Market Size of Hot Flashes associated with Post Menopause in the UK, USD Millions (2016-2027)
Table 44 Market Size of Hot Flashes associated with Post Menopause by therapies in UK, USD Millions (2016-2027)
Table 45 Market Size of Hot Flashes associated with Post Menopause in Japan, USD Millions (2016-2027)
Table 46 Market Size of Hot Flashes associated with Post Menopause by therapies in Japan, USD Millions (2016-2027)
Figure 1 Stages of menopause
Figure 2 Vasomotor Symptoms
Figure 3 The 3 major components involved in thermoregulatory function.
Figure 4 Relationship between estrogen and a woman's reproductive phases and the occurrence of hot flashes.
Figure 5 Maintenance of core body temperature (CBT) is critical to organ integrity and optimal function.
Figure 6 Risk factors for VMS.
Figure 7 Effects of VMS
Figure 8 Impact of VMS on QOL
Figure 9 Breast Cancer therapies causing Menopause
Figure 10 Total Prevalent Patient Population of Hot Flashes associated with Post-menopause in 7MM Countries (2016-2027)
Figure 11 Prevalence of Hot Flashes Associated with Postmenopause in the United States (2016-2027)
Figure 12 Severity Specific Prevalence of Hot Flashes associated with Postmenopause in the United States (2016-2027)
Figure 13 Prevalence of Hot Flashes associated with Post Menopause in Germany (2016-2027)
Figure 14 Severity Specific Prevalence of Hot Flashes Associated with Postmenopause in Germany (2016-2027)
Figure 15 Prevalence of Hot Flashes Associated with Post-menopause in France (2016-2027)
Figure 16 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in France (2016-2027)
Figure 17 Prevalence of Hot Flashes Associated with Post-menopause in Italy (2016-2027)
Figure 18 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Italy (2016-2027)
Figure 19 Prevalence of Hot Flashes Associated with Post-menopause in Spain (2016-2027)
Figure 20 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Spain (2016-2027)
Figure 21 Prevalence of Hot Flashes Associated with Post-menopause in the UK (2016-2027)
Figure 22 Severity Specific Prevalence of Hot Flashes Associated with Postmenopause in the UK (2016-2027)
Figure 23 Prevalence of Hot Flashes Associated with Post-menopause in Japan (2016-2027)
Figure 24 Severity Specific Prevalence of Hot Flashes Associated with Post-menopause in Japan (2016-2027)
Figure 25 Non-hormonal pharmacological treatments for vasomotor symptoms
Figure 26 Unmet Needs of Hot Flashes
Figure 27 Market Size of Hot Flashes associated with post menopause in USD Million (2016-2027)
Figure 28 Market Size of Hot Flashes associated with Post Menopause by therapies in the 7MM, USD Millions (2016-2027)
Figure 29 Market Size of Hot Flashes associated with Post Menopause in the US, USD Millions (2016-2027)
Figure 30 Market Size of Hot Flashes associated with Post menopause by therapies in the US, USD Millions (2016-2027)
Figure 31 Market Size of Hot Flashes associated with Post menopause in Germany, USD Millions (2016-2027)
Figure 32 Market Size of Hot Flashes associated with Post Menopause by therapies in Germany, USD Millions (2016-2027)
Figure 33 Market Size of Hot Flashes associated with Post Menopause in France, USD Millions (2016-2027)
Figure 34 Market Size of Hot Flashes associated with Post Menopause by therapies in France, USD Millions (2016-2027)
Figure 35 Market Size of Hot Flashes associated with Post menopause in Italy, USD Millions (2016-2027)
Figure 36 Market Size of Hot Flashes associated with Post Menopause by therapies in Italy, USD Millions (2016-2027)
Figure 37 Market Size of Hot Flashes associated with Post Menopause in Spain, USD Millions (2016-2027)
Figure 38 Market Size of Hot Flashes associated with Post Menopause by therapies in Spain, USD Millions (2016-2027)
Figure 39 Market Size of Hot Flashes associated with Post Menopause in the UK, USD Millions (2016-2027)
Figure 40 Market Size of Hot Flashes associated with Post Menopause by therapies in UK, USD Millions (2016-2027)
Figure 41 Market Size of Hot Flashes associated with Post Menopause in Japan, USD Millions (2016-2027)
Figure 42 Market Size of Hot Flashes associated with Post Menopause by therapies in Japan, USD Millions (2016-2027)
Figure 43 Market Drivers
Figure 44 Market Barriers
